Mensinger Mike 4/A

What Happened

• Mike Mensinger, Chief Product Officer of Beta Bionics (BBNX), received a derivative equity award on 2026-02-27 covering 91,520 shares. The award was reported at $0.00 per share (no cash exchanged at grant).
• This filing is an amendment to correct the number of shares reported on the original Form 4 filed March 3, 2026.

Key Details

• Transaction date: 2026-02-27; Price reported: $0.00 (derivative/award).
• Vesting: The footnote states the shares subject to the option will vest in 36 equal monthly installments beginning March 1, 2026.
• Shares owned after the transaction: not specified in this filing.
• Filing timeliness: original Form 4 was filed March 3, 2026 (within the two-business-day window); this Form 4A (amendment) was filed March 13, 2026 to correct the reported share count.

Context

• This was a derivative award (an option-like grant), not an open-market purchase or sale. No cash was paid at grant and no shares were immediately issued; the economic value depends on future stock price and vesting/exercise terms.
• Amended filings like this typically correct reporting details and do not by themselves indicate a change in insider intent.